Primus In News
Tarnished by cough syrup deaths, India’s pharma industry tries to look beyond the stupor
21-07-2023
Nilaya Varma, Co-Founder and CEO of Primus Partners shares his views on the impact of the COVID-19 pandemic and the Russia-Ukraine war on vaccine exports from India, especially to African and Commonwealth of Independent States (CIS) countries. In addition, he stresses that the increasing cost of raw materials and the withdrawal of GST exemption has exacerbated challenges for Indian pharma companies. Read Now!
Explore Related Insights
- Leading Voices from Bollywood Agree on the Need for Doing More for Positive Portrayal of Women in Media and Entertainment
- Why the I&B Ministry’s landing-page clampdown has divided India’s TV ecosystem
- Delhi High Court Sides With Go First’s Lessors For Aircraft Inspection
- Vaccine Rollout: A Shot In The Arm
